menu
    • menu
    [{"orgOrder":0,"company":"NextPoint","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"NextPoint","amount2":0.080000000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"NextPoint \/ Leaps by Bayer","highestDevelopmentStatusID":"1","companyTruncated":"NextPoint \/ Leaps by Bayer"},{"orgOrder":0,"company":"NextPoint","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"NPX267","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"NextPoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextPoint \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NextPoint \/ Not Applicable"},{"orgOrder":0,"company":"NextPoint","sponsor":"Catalio Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Series B Financing","leadProduct":"NPX267","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"NextPoint","amount2":0.12,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"NextPoint \/ Catalio Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"NextPoint \/ Catalio Capital Management"},{"orgOrder":0,"company":"NextPoint","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"NPX887","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"NextPoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextPoint \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NextPoint \/ Not Applicable"},{"orgOrder":0,"company":"NextPoint","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"NPX887","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NextPoint","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextPoint \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NextPoint \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by NextPoint

    Menu

    NextPoint

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NextPoint

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            NextPoint

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPX887

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NextPoint Therapeutics Doses First Patient in Phase 1a/b Trial of NPX887

                            Details : NPX887 is a fully human monoclonal antibody targeting HHLA2 (B7-H7), under evaluation for various solid tumors, including non-small cell lung cancer and renal cell carcinoma.

                            Brand Name : NPX887

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 20, 2024

                            Lead Product(s) : NPX887

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NextPoint

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            NextPoint

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPX267

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Catalio Capital Management

                            Deal Size : $122.5 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            NextPoint Therapeutics Closes Series B Financing Extension Led By Catalio Capital

                            Details : Funds will support the development of NPX267, targeting metastatic solid tumors, including EGFR-mutant non-small cell lung cancer and HHLA2-expressing metastatic neoplasms.

                            Brand Name : NPX267

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 14, 2024

                            Lead Product(s) : NPX267

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Catalio Capital Management

                            Deal Size : $122.5 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NextPoint

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            NextPoint

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPX887

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NextPoint Therapeutics Announces IND Clearance from the FDA to Advance NPX887, a Novel Therapeutic Targeting H...

                            Details : NextPoint investigational product NPX887 is a fully human monoclonal antibody targeting HHLA2 (B7-H7). Currently evaluating under the IND enabling stage for the treatment of solid tumors known to express HHLA2, a tumor antigen strongly upregulated in man...

                            Brand Name : NPX887

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 07, 2023

                            Lead Product(s) : NPX887

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            NextPoint

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            NextPoint

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPX267

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX267, a Novel Therapeut...

                            Details : NPX267 is a first-in-class monoclonal antibody targeting KIR3DL3, the inhibitory receptor for the HHLA2 pathway (B7-H7), and is designed to prevent immune escape in solid tumors.

                            Brand Name : NPX267

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 17, 2023

                            Lead Product(s) : NPX267

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NextPoint

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            NextPoint

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Leaps by Bayer

                            Deal Size : $80.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures t...

                            Details : The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 10, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Leaps by Bayer

                            Deal Size : $80.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth